Joint Diseases, Muskuloskeletal Diseases, Osteoarthritis, Psoriasis, Skin Diseases
Conditions
Keywords
Chondroitin sulphate, Knee osteoarthritis, Psoriasis
Brief summary
The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.
Interventions
Chondroitin sulphate 800 mg/day
DRUGPlacebo
Sponsors
Bioiberica
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary knee OA according to ACR criteria; * OA of radiological stages 1 to 3 according to Kellgren-Lawrence; * VAS of pain ≥30; * PASI ≥ 5.
Exclusion criteria
* Known allergy to chondroitin sulphate; * Other bone and articular diseases such as chondrocalcinosis, Paget's disease, rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's disease; * Patients with skin conditions that could interfere in the clinical trial evaluation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Huskisson Visual Analogue Scale | Monthly |
| Psoriasis Area and Severity Index | Monthly |
Secondary
| Measure | Time frame |
|---|---|
| SF-36 Health Questionaire | 3 months |
| Overall Lession Severity Scale | Monthly |
| Physician's Global Assessment of improvement | Monthly |
| Lequesne Index | Monthly |
| Dermatology Life Quality Index | Monthly |
| Tolerability | Monthly |
| Adverse events | Monthly |
| Histological assessment of skin biopsies | 3 months |
| Use of rescue medication | Monthly |
Countries
Spain
Outcome results
None listed